Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR
- 10 July 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 23 (2), 396-399
- https://doi.org/10.1038/leu.2008.183
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitorsOncogene, 2007
- Microfluidic Digital PCR Enables Multigene Analysis of Individual Environmental BacteriaScience, 2006
- Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(ϕ)-LMC GROUP)Leukemia, 2006
- Evaluating markers for the early detection of cancer: overview of study designs and methodsClinical Trials, 2006
- High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapyPublished by American Society of Hematology ,2005
- ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid LeukemiaJournal of Clinical Oncology, 2005
- Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutationsBlood, 2004
- Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosisBlood, 2003